BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $63.00
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target hoisted by Piper Sandler from $46.00 to $63.00 in a research report released on Wednesday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock. A number of other research analysts have also recently weighed in on BBIO. Scotiabank lifted their price objective on […]
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target hoisted by Piper Sandler from $46.00 to $63.00 in a research report released on Wednesday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock. A number of other research analysts have also recently weighed in on BBIO. Scotiabank lifted their price objective on […]
